Thus, ku-0063794, as a novel ATP-competitive mTOR inhibitor, showed marked antiproliferative effects and induced G1 cell cycle arrest both in EGFR TKI-sensitive and -resistant NSCLC cells in vitro. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.